CA2645302C - Diagnosis and prognosis of dipeptidyl peptidase-associated disease states - Google Patents
Diagnosis and prognosis of dipeptidyl peptidase-associated disease states Download PDFInfo
- Publication number
- CA2645302C CA2645302C CA2645302A CA2645302A CA2645302C CA 2645302 C CA2645302 C CA 2645302C CA 2645302 A CA2645302 A CA 2645302A CA 2645302 A CA2645302 A CA 2645302A CA 2645302 C CA2645302 C CA 2645302C
- Authority
- CA
- Canada
- Prior art keywords
- dpp
- activity
- measured
- isoforms
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78192406P | 2006-03-13 | 2006-03-13 | |
| US60/781,924 | 2006-03-13 | ||
| US80439706P | 2006-06-09 | 2006-06-09 | |
| US60/804,397 | 2006-06-09 | ||
| US89276707P | 2007-03-02 | 2007-03-02 | |
| US60/892,767 | 2007-03-02 | ||
| PCT/US2007/006653 WO2007106595A1 (en) | 2006-03-13 | 2007-03-13 | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2645302A1 CA2645302A1 (en) | 2007-09-20 |
| CA2645302C true CA2645302C (en) | 2017-07-11 |
Family
ID=38265130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2645302A Active CA2645302C (en) | 2006-03-13 | 2007-03-13 | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8652789B2 (https=) |
| EP (1) | EP1994415B9 (https=) |
| JP (1) | JP5410955B2 (https=) |
| KR (1) | KR101376471B1 (https=) |
| CN (1) | CN101460851B (https=) |
| AU (1) | AU2007225054B2 (https=) |
| BR (1) | BRPI0708900A2 (https=) |
| CA (1) | CA2645302C (https=) |
| ES (1) | ES2549860T3 (https=) |
| MX (1) | MX2008011665A (https=) |
| WO (1) | WO2007106595A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527649T3 (es) * | 2007-12-10 | 2015-01-28 | F. Hoffmann-La Roche Ag | Panel de marcadores para el cáncer colorrectal |
| ES2533428T3 (es) * | 2009-05-04 | 2015-04-10 | F. Hoffmann-La Roche Ag | Uso de DPPIV/Seprasa como un marcador para el cáncer |
| JP6065172B2 (ja) * | 2010-10-22 | 2017-01-25 | 国立大学法人名古屋大学 | 微小血管障害又はその関連疾患のバイオマーカー |
| US20140273008A1 (en) * | 2013-03-15 | 2014-09-18 | Molecular Bioproducts, Inc. | Methods to assess enzyme activity using mass spectrometric immunoassay |
| EP3314004A1 (en) * | 2015-06-26 | 2018-05-02 | DuPont Nutrition Biosciences ApS | Aminopeptidases for protein hydrolyzates |
| AU2017252212B2 (en) * | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| CN110426518A (zh) * | 2019-07-19 | 2019-11-08 | 宁波熙宁检测技术有限公司 | 一种定量检测人类血浆中dpp-4酶活性的方法 |
| EP4308937B1 (en) * | 2021-03-16 | 2026-02-04 | Astrazeneca AB | System and method for online detection of a post-translational modification of a polypeptide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900662A (en) | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
| US5382515A (en) | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Creative kinase-MB immunoassay for myocardial infarction and reagents |
| US5382522A (en) | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents |
| EP1631680A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
-
2007
- 2007-03-13 CN CN200780016051.1A patent/CN101460851B/zh active Active
- 2007-03-13 WO PCT/US2007/006653 patent/WO2007106595A1/en not_active Ceased
- 2007-03-13 AU AU2007225054A patent/AU2007225054B2/en active Active
- 2007-03-13 JP JP2009500509A patent/JP5410955B2/ja active Active
- 2007-03-13 KR KR1020087024813A patent/KR101376471B1/ko active Active
- 2007-03-13 EP EP07753293.5A patent/EP1994415B9/en not_active Not-in-force
- 2007-03-13 ES ES07753293.5T patent/ES2549860T3/es active Active
- 2007-03-13 US US11/724,029 patent/US8652789B2/en active Active
- 2007-03-13 BR BRPI0708900-7A patent/BRPI0708900A2/pt not_active Application Discontinuation
- 2007-03-13 CA CA2645302A patent/CA2645302C/en active Active
- 2007-03-13 MX MX2008011665A patent/MX2008011665A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009529884A (ja) | 2009-08-27 |
| AU2007225054A1 (en) | 2007-09-20 |
| CA2645302A1 (en) | 2007-09-20 |
| US8652789B2 (en) | 2014-02-18 |
| EP1994415B9 (en) | 2015-12-16 |
| ES2549860T3 (es) | 2015-11-02 |
| KR101376471B1 (ko) | 2014-03-27 |
| JP5410955B2 (ja) | 2014-02-05 |
| CN101460851B (zh) | 2016-09-21 |
| EP1994415B1 (en) | 2015-07-29 |
| WO2007106595A1 (en) | 2007-09-20 |
| AU2007225054B2 (en) | 2012-08-16 |
| MX2008011665A (es) | 2008-10-08 |
| KR20090008218A (ko) | 2009-01-21 |
| EP1994415A1 (en) | 2008-11-26 |
| US20070264671A1 (en) | 2007-11-15 |
| CN101460851A (zh) | 2009-06-17 |
| BRPI0708900A2 (pt) | 2011-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2645302C (en) | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states | |
| Lahiri et al. | Systemic inflammatory response syndrome after major abdominal surgery predicted by early upregulation of TLR4 and TLR5 | |
| Ghallab et al. | Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions | |
| Morgan et al. | Role of arterial telomere dysfunction in hypertension: relative contributions of telomere shortening and telomere uncapping | |
| Esteghamat et al. | CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation | |
| US20190264283A1 (en) | URINE EXOSOME mRNAS AND METHODS OF USING SAME TO DETECT DIABETIC NEPHROPATHY | |
| JP2002131322A5 (https=) | ||
| AU2020388534A1 (en) | Device and method for detecting of brain injury in a subject | |
| Koh et al. | Single cell transcriptomes derived from human cervical and uterine tissue during pregnancy | |
| Jimbo et al. | Placenta increta: postpartum monitoring of plasma cell-free fetal DNA | |
| Soluble Insulin Receptor Study Group | Soluble insulin receptor ectodomain is elevated in the plasma of patients with diabetes | |
| Kumar et al. | Estimation of YKL-40 levels in serum and gingival crevicular fluid in chronic periodontitis and type 2 diabetes patients among south Indian population: A clinical study | |
| Saadi et al. | Predictors of successful outcome after adrenalectomy for unilateral primary aldosteronism | |
| Balistreri et al. | The role of inflammation in type A aortic dissection: a pilot study | |
| RU2000119129A (ru) | Молекула днк, кодирующая мутантный препронейропептид y, мутантный сигнальный пептид и их применения | |
| AL-khaykanee et al. | A review about liver function tests | |
| Evangelopoulos et al. | The impact of demographic characteristics and lifestyle in the distribution of cystatin C values in a healthy Greek adult population | |
| Abdulraheem et al. | Diagnostic value of Interleukin-40 and Interleukin-41 for Diabetic Kidney Disease and Diabetes | |
| Van Langendonckt et al. | Identification of novel antigens in blood vessels in rectovaginal endometriosis | |
| Hyodo et al. | Molar DNA in maternal serum in a case of 46, XY heterozygous complete hydatidiform mole coexisting with a 46, XX twin live fetus | |
| Jankowski et al. | Biomarkers identifying deterioration of kidney graft function—usefulness of “liquid biopsy” | |
| US7759086B2 (en) | Diagnostic method for chronic fatigue syndrome by measuring elastase | |
| Shenoy et al. | Lipid-bound sialic acid in psoriasis and its correlation with disease severity | |
| Chauhan et al. | Spot Urine Protein to Creatinine Ratio in Patients with Urinary Tract Infection | |
| Kalpidis | Role of Salivary Biomarkers in Diagnosis and Monitoring of Patients with Autoimmune Diseases: A Systematic Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD Year of fee payment: 18 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD Year of fee payment: 19 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260226 |